The immune microenvironment of pancreatic ductal adenocarcinoma (PDA) is comprised of a heterogeneous population of cells that are critical for disease evolution. Prominent among these are the specialized CD1d hi CD5 + regulatory B (B reg ) cells that exert a pro-tumorigenic role by promoting tumor cell proliferation. Dissecting the molecular pathways regulating this immune sub-population can thus be valuable for uncovering potential therapeutic targets. Here, we investigate Bruton's tyrosine kinase (BTK), a key B-cell kinase, as a potential regulator of CD1d hi CD5 + B reg differentiation in the pancreatic tumor microenvironment. Treatment of cytokine-induced B cells in vitro with the high specificity BTK inhibitor Tirabrutinib inhibited CD1d hi CD5 + B reg differentiation and production of IL-10 and IL-35, essential mediators of B reg immunosuppressive functions. The BTK signaling pathway was also found to be active in vivo in PanIN-associated regulatory B cells. Tirabrutinib treatment of mice bearing orthotopic Kras G12D -pancreatic lesions severely compromised stromal accumulation of the CD1d hi CD5 + B reg population. This was accompanied by an increase in stromal CD8 + IFNγ + cytotoxic T cells and significant attenuation of tumor cell proliferation and PanIN growth. Our results uncover a novel role for BTK in regulating CD1d hi CD5 + B reg differentiation and emphasize its potential as a therapeutic target for pancreatic cancer.
Introduction
Pancreatic ductal adenocarcinoma (PDA), the most common type of pancreatic cancer, is one of the most aggressive solid malignancies [1] . With a dismal 5-year survival rate of 5-7%, it is currently the third leading cause of cancerrelated mortality [2] . In about 95% of cases, PDA initiates with the acquisition of an oncogenic mutation in KRAS and progresses through a distinct series of accumulating genetic and morphological alterations marked by tumor cell proliferation, apoptotic evasion, metabolic reprogramming, and metastatic dissemination [3] .
Additionally, PDA evolution is characterized by extensive stromal remodeling, with intense desmoplasia and robust immune cell infiltration [4, 5] . The immune composition of the PDA microenvironment is sculpted early during transformation, culminating in the accumulation of immunosuppressive cell populations including regulatory T (T reg ) cells, myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs) [6] [7] [8] . The tumorprotective role of these distinct cell populations in pancreatic neoplasia has been a subject of intense scrutiny. For instance, production of Granulocyte-macrophage colony stimulating factor (GM-CSF) by KRas G12D -bearing pancreatic tumor cells promotes recruitment of MDSCs to the tumor microenvironment (TME), which in turn promote tumor growth by suppressing immune clearance by CD8 + cytotoxic T (Tc) cells [7] . Additionally, TAMs in the PDA microenvironment display a pro-tumorigenic M2-type polarization, which is characterized by expression of immunosuppressive molecules, including interleukin-10 (IL-10), Arginase 1, Transforming growth factor-β (TGFβ) and C-C motif chemokine 22 and promote a tolerant Th2 immune response [9] . In keeping with the overall immune suppressive nature of the TME, the Th subtypes associated with pancreatic lesions are skewed towards the pro-tumorigenic Th2, T reg , and Th17 cells, relative to the Th1 population [6, 10, 11] . Oncogenic Kras expression in cancer cells directly induces T reg differentiation, which inhibits autoreactive Tc cells, thereby preventing immune clearance of the tumor [12] [13] [14] . Furthermore, activation of KRas G12D expression specifically upon induction of pancreatitis, a major PDA risk factor, results in expansion of stromal CD4 + T reg and CD4 + Th17 cell populations. Genetic depletion of CD4 + T cells in this PDA model resulted in de-repression of stromal CD8 + Tc cells and subsequent attenuation of tumor progression [12] .
Recently, tumor-infiltrating lymphocytic B (TIL-B) cells have been identified as significant positive regulators of PDA initiation and progression [15] [16] [17] . Robust B-cell infiltration is observed in the microenvironment of patient PDA samples. B-cell depletion in early and advanced stage mouse models of pancreatic cancer was found to significantly attenuate tumor establishment and progression [17] . Furthermore, in the LSL-Kras G12D ; p48 Cre (KC) mouse model of pancreatic intraepithelial neoplasia (PanIN), we have previously uncovered a crucial role for a specialized B-cell subset in PanIN evolution [16] . The PanIN microenvironment is enriched in IL-10 and IL-35 producing immunosuppressive CD1d hi CD5 + B regulatory (B reg ) cells, loss of which severely attenuates PanIN growth. We identified IL-35 as a prominent downstream effector of CD1d hi CD5 + B reg function in pancreatic tumorigenesis by directly stimulating tumor cell proliferation [16] . Although the stromal-derived chemokine CXCL13 was found to potentiate B-cell recruitment to the PanIN microenvironment [16] , the molecular mechanisms regulating their further differentiation and function in the PanIN stroma remain unknown.
In light of these observations, we sought to dissect the molecular mechanisms regulating CD1d hi CD5 + B reg expansion in the PanIN milieu. As a cytoplasmic nonreceptor tyrosine kinase, the Bruton's tyrosine kinase (BTK) enzyme plays a central role in regulating B-cell development and function, serving as a downstream signal transducer for a variety of cytokine and chemokine receptors, antigen receptors, and integrins [18] . BTK-mediated signaling is in turn transmitted through several prominent downstream effectors including phosphoinositol-3 kinase-AKT, phospholipase-C (PLC), protein kinase C and nuclear factor κB (NF-κB) [19, 20] . For instance, BTK activation upon antigen-mediated B-cell receptor (BCR) engagement promotes B-cell survival, proliferation, and antibody production through PLCγ2 and subsequent NF-κB activation [21] . Additionally, BTK is also a mediator of the Toll-like receptor (TLR) signaling pathway, wherein in complex with Myd88 it activates the NF-κB transcription factor and subsequently regulates expression of pro-and antiinflammatory cytokines [22, 23] .
Although BTK-mediated regulation of the immunosuppressive cytokine IL-10 has been described in macrophages and B cells [24, 25] , its role in regulating B reg biology remains unexplored. In the current study, we have uncovered a role for BTK as a critical regulator of CD1d hi CD5 + B reg differentiation and immunosuppressive function. Furthermore, our findings point to a potential therapeutic strategy for targeting pancreatic cancer.
Results and discussion
We initiated our study by first investigating whether BTK activity is necessary for CD1d hi CD5 + B reg evolution. To this end, we assessed the effect of the BTK inhibitor tirabrutinib on naive murine splenic B cells treated with IL-6, IL-1β, and α-CD40 antibody. These inflammatory signals, which are also enriched in the PanIN stroma [26] , have been shown to induce differentiation of mouse splenic B reg cells [27] . Furthermore, both CD40 and the IL-6 receptor activate BTK [28, 29] , as do the downstream effectors of the IL-1 receptor Myd88 and IRAK-1 [30] , suggesting a role for BTK in B reg differentiation induced by these pathways.
As illustrated in Fig. 1a, b and Supplementary Figure  S1a , inflammatory stimulation of splenic B cells from naive mice upregulated BTK activation as measured by pBTK (Y223) expression [19] . Cytokine treatment of B cells did not alter total BTK protein levels ( Supplementary Fig. S1a ). This increase was accompanied by an expansion of the CD1d hi CD5 + B reg population ( Fig. 1c, d ). Significantly, inhibition of BTK activation by tirabrutinib ( Fig. 1a, b , Supplementary Fig. S1a ) attenuated cytokine-induced CD1d hi CD5 + B reg differentiation ( Fig. 1c, d ). Furthermore, tirabrutinib markedly downregulated expression of both CD1d hi CD5 + B reg functional markers, IL-10 ( Fig. 1e , Supplementary Fig. S1b ) and IL-35 (heterodimer of Ebi3 and p35, encoded by the Ebi3 and IL12A genes, respectively) ( Fig. 1f , g), which are critical mediators of CD1d hi CD5 + B reg immunosuppressive function. Collectively, our results directly implicate the BTK signaling pathway in promoting CD1d hi CD5 + B reg differentiation and production of the immunomodulatory cytokines IL-10 and IL-35.
To ascertain whether CD1d hi CD5 + B reg evolution in pancreatic neoplasia is also regulated by BTK signaling, we first assessed the status of BTK activation in PanINassociated B reg cells. Immunostaining of tissue sections from LSL-Kras G12D ; p48-Cre (KC) [31] mice pancreata displayed colocalization of pBTK (Y223) with IL-10 producing CD19 + B cells ( Fig. 2a, Supplementary Fig. S2a ). We did not detect significant differences in overall BTK levels between regulatory and non-regulatory B-cell populations in the KC pancreatic stroma ( Supplementary Fig.  S2a ). Furthermore, flow cytometric analysis of the pancreata of KC mice ( Fig. 2b, Supplementary Fig. S2b ), as well as orthotopically implanted Kras G12D -PanIN lesions [7] ( Supplementary Fig. S2c ) revealed the expression of activated pBTK (Y223) specifically in PanIN-associated CD1d hi CD5 + B reg cells. Plausible mechanisms for this observed BTK activation in stromal B cells include CD40, TLR4, and IL-6 signaling, all of which are enriched in the PanIN stroma [28] [29] [30] [32] [33] [34] and shown to regulate BTK activity. Interestingly, the TLR4 downstream effectors Myd88 and IRAK4 that mediate BTK phosphorylation are also interacting partners of the IL-1β receptor IL1R1. As IL-1β is reported to be produced in pancreatic tumors [26] , we sought to assess the contribution of IL-1β to BTK activation in PanIN-stromal B cells. Orthotopically implanted Kras G12D -PanIN lesions were significantly enriched in IL-1β protein, relative to sham injections ( Supplementary Fig.  S2d ). As outlined in Fig. 2c , Kras G12D -PanIN lesions implanted in wild-type or IL1R1-/mouse pancreas were analyzed for BTK (Y223) phosphorylation in PanINassociated B cells. IL1R1-/stromal B cells displayed significantly lower pBTK (Y223) levels relative to wild-type control (Fig. 2d ), indicating that IL-1 signaling in the PanIN TME contributes to BTK activation in stromal B cells.
We next sought to determine the functional significance of BTK activity in PanIN-associated CD1d hi CD5 + B reg cells. Wild-type mice bearing orthotopically implanted Kras G12D -PanIN lesions were treated with tirabrutinib as outlined ( Fig. 3a) . Tirabrutinib inhibited BTK activation as measured by pBTK (Y223) staining in the PanIN stroma ( Fig. 3b ) and more specifically in infiltrating B cells ( Fig.  3c , Supplementary Fig. S3a ). Considering the crucial role of BTK in B-cell proliferation and survival, we analyzed the effect of tirabrutinib treatment on both CD1d hi CD5 + B reg cells and the overall tumor-infiltrating B-cell population. BTK inhibition did not significantly alter the total CD19 + B-cell fraction in the tumor stroma after 2 weeks of tirabrutinib treatment ( Fig. 3d ; Supplementary Fig. S3b, S3c ). On the other hand, the CD1d hi CD5 + B reg subset displayed remarkable sensitivity to BTK inhibition, with a significant decrease in the stromal population within 2 weeks of treatment, relative to the vehicle control ( Fig. 3e ; Supplementary Fig. S3d, S3e ). Prolonged tirabrutinib treatment for 4 weeks induced a small but significant decrease in stromal CD19 + B cells ( Fig. 3d ; Supplementary Fig. S3b ) while markedly decreasing the CD1d hi CD5 + B reg population, relative to vehicle control ( Fig. 3e ; Supplementary Fig.  S3d ). CD1d hi CD5 + B reg cells primarily mediate immunosuppression by inhibiting Tc cell activation [35] . Consistent with this, CD1d hi CD5 + B reg depletion upon BTK inhibition was accompanied by a significant increase in the IFNγ + CD8 + Tc cell population ( Fig. 3f; Supplementary Fig. S3f) without altering the overall CD8 + Tc cell proportion ( Supplementary Fig. S3g ), further implicating BTK in the immunomodulatory function of CD1d hi CD5 + B reg .
The physiologic importance of CD1d hi CD5 + B reg attenuation upon BTK inhibition is highlighted by the reduced growth of the PanIN lesions ( Fig. 4a, b ). Tirabrutinib significantly inhibited proliferation of the tumor cells, relative to the vehicle control ( Fig. 4c, d) , as measured by immunohistochemical staining of the proliferation marker phospho-Histone H3 staining in the Kras G12D -transformed epithelia. We did not detect induction of apoptosis upon tirabrutinib treatment, as assessed by cleaved caspase 3 staining (data not shown). This is consistent with our previously reported observation that the attenuation of PanIN growth in the absence of stromal CD1d hi CD5 + B reg cells is due to inhibition of epithelial proliferation [16] . Taken together, our observations implicate BTK in the development of pancreatic neoplasia through the regulation of CD1d hi CD5 + B reg differentiation in the PanIN microenvironment.
Given the critical role of immunomodulation in promoting pancreatic tumorigenesis, understanding the molecular mechanisms mediating this process is essential for developing effective immunotherapeutic strategies for combating the disease. Initial efforts with checkpoint inhibitors, such as α-CTLA-4 and α-PD-1, which show promise in other cancers have proved ineffective for pancreatic cancer [36] , underscoring the need to identify and therapeutically explore additional targets. [31] pancreata to detect colocalization of pBTK (Y223) with IL-10 and B-cell marker CD19. Mice pancreata were fixed, processed, and stained as described previously [7] . Antibodies used were pBTK (Y223) (1:200, 109336, LSBio, Seattle, WA, USA), CD19 (1:50, 550284, BD Biosciences, San Jose, CA, USA), and IL-10 (1:50, sc-365858, Santa Cruz Biotechnology, Dallas, TX, USA). Slides were examined and imaged on a Nikon Eclipse Ti2 microscope. Scale bar, 100 μm. b Representative intracellular flow cytometric analysis of pBTK (Y223) in B cells from pancreata of KC mice [31] , as described previously [7] . Single-cell suspension from pancreatic tissue was prepared as described previously [7] and stained with the following antibodies for flow cytometry analysis: CD45 (2D1, 368521, Biolegend); CD19 (6D5, #115506, Biolegend), CD1d (1B1, 123509, Biolegend), CD5 (53-7.3, 100621, Biolegend), pBTK (Y223) (N35-86, 564848, BD). After gating on the CD45 + and CD19 + population, cells were analyzed for pBTK (Y223) expression in CD1d hi CD5 + B regs .
Also shown are isotype controls for pBTK (Y223) staining. Graph represents quantification of FACS analysis, indicating percentage of CD1d hi CD5 + B reg cells expressing pBTK (Y223) in KC mice (2-3 month old, N = 5). Error bars indicate SD. P-value calculated using Student's t-test (two-tailed, unpaired). **P ≤ 0.01. c Experimental schematic for pBTK analysis of Kras G12D -PDEC orthotopic lesions in wild-type or IL1R1-/mice. d Western blot analysis of pBTK expression in PanIN-associated wild-type or IL1R1-/-B cells. Total B cells were isolated from 2-week-old pancreatic orthotopic lesions implanted in wild-type (C57BL/6J, Jackson Laboratory, Bar Harbor, ME, USA) or IL1R1-/mice (B6.129S7-Il1r1tm1Imx/J, Jackson Laboratory) (N = 5) using CD45R (B220)-linked MACS beads (130-049-501, Miltenyi) and MS columns (130-042-201, Miltenyi) as per manufacturer's instructions. Isolated cells were lysed in sample buffer and analyzed by immunoblotting on a LiCor Odyssey imager using the following antibodies: Phospho-BTK (Tyr 223) (5082S, Cell Signaling Technologies, Danvers, MA) and BTK (8547S, Cell Signaling Technologies) Fig. 3 BTK inhibition downregulates CD1d hi CD5 + regulatory B cells in PanIN stroma. a Schema for tirabrutinib administration in PanIN-bearing mice (10 mg/kg; QD; administered orally), initiated 1 week post Kras G12D -PDEC orthotopic implantation. Briefly, 10 6 Kras G12D PDECs were injected in the pancreas of 8 weeks old, female C57BL/6 mice (Charles River). PanIN-bearing mice were randomly assigned to control and experimental groups for subsequent drug treatment. Sample sizes for experiments were determined without formal power calculation. Investigators were not blinded to group allocation or outcome assessment. b Representative immunohistochemical detection of stromal pBTK (Y223) in Kras G12D -PDEC orthotopic lesions treated with vehicle or tirabrutinib for 2 weeks. Mice pancreata were fixed, processed, and stained by immunohistochemistry (IHC) as described previously [7] . Antibodies by increased interferon-γ (IFNγ) production in CD8 + T cells. Our results thus indicate that combining the cytostatic effect of BTK inhibitors with checkpoint-directed immunotherapy, which can further enhance the Tc cell response, may provide an effective multipronged approach for PDA therapy. BTK inhibitors are already approved as monotherapy for B-cell malignancies [37] , whereas clinical trials assessing the efficacy of BTK inhibitors in combination with anti-PD-1 immunotherapy are currently underway (e.g., clinicaltrials.gov; NCT02362048).
In addition to pancreatic cancer, B reg cells have also been found to promote other tumor types including melanoma, mammary, and squamous cell carcinoma [38] . As such, understanding the molecular pathways regulating their development and function is of great importance. Unlike T reg cells, B reg lymphocytes are a heterogeneous population without well-defined precursors or developmental lineage [35] . Instead, these cells exhibit great plasticity, differentiating in response to extracellular inflammatory cues from their microenvironment. Although some of these inflammatory signals have been described, the downstream molecular pathways regulating the process remain to be elucidated. We have identified BTK as a direct cell-intrinsic regulator of CD1d hi CD5 + B reg differentiation. BTK inhibition downregulates expression of the cytokines IL-10 and IL-35, expanding its potential role to additional immunosuppressive B-cell subsets such as the i35-B reg population, as well as in various autoimmune conditions [39, 40] . Fig. 4 Tirabrutinib treatment inhibits proliferation and restricts growth of Kras G12D -PanIN lesions. a Immunohistochemical detection of CK8 in sections of Kras G12D -PDEC orthotopic lesions treated with tirabrutinib or vehicle control for 2 and 4 weeks as indicated. Representative images are shown. Mice pancreata were fixed, processed, and stained by immunohistochemistry (IHC) as described previously [7] . Antibody used was CK8 (1:200, TROMA-Ic, DSHB, University of Iowa; Iowa City, IA, USA). Slides were examined and imaged on a Nikon Eclipse 80i microscope. Scale bar, 200 μm. b Graph depicts quantification of data from a indicating % CK8 + area within the lesion, determined using ImageJ software. (N = 9, Vehicle, 2 weeks; N = 9, tirabrutinib treatment, 2 weeks; N = 11, Vehicle, 4 weeks; N = 10, tirabrutinib treatment, 4 weeks). Error bars indicate SD; P-value calculated using Student's t-test (two-tailed, unpaired). Data representative of two independent experiments. ***P ≤ 0.001, c IHC staining for phospho-Histone H3 (p-HH3) of Kras G12D -PDEC orthotopic lesions treated with tirabrutinib or vehicle control for 2 weeks. Representative images are shown. Antibody used was phospho-Histone H3 (1:200, 06-570, Millipore). Scale bars, 200 μm. d Graph depicts quantification of data in c indicating percent positive p-HH3 staining in epithelial cells using ImageJ software (10 fields of view per animal; N = 7). Error bars indicate SD; P-values determined by the Student's t-test (two-tailed, unpaired); ****P ≤ 0.0001. Data representative of two independent experiments Further characterization of this pathway would not only enable a deeper understanding of this hitherto elusive B-cell sub-population but also expand our repertoire of potential therapeutic candidates for immunotherapy.
